Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis.

Front Pharmacol · 2023 · PMC10442954 · PMID 37614310

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

It can be seen from the table that the differences between the different drugs in terms of MACE did not reach statistical significance, but in terms of all-cause mortality, the use of JAK inhibitors may increase overall mortality compared to adalimumab (OR: 1.7, 95% CI: 1.02–2.81).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.